Company intelligence / Profile preview

Visura Technologies

Minneapolis, Minnesota, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Clinical data presented at major cardiology meetings (such as ASE 2023 and 2025) demonstrate that the TEECAD system improves first-pass intubation success from 44% to 91% and reduces oropharyngeal injuries by 50%. Use in real-world settings was associated with safe and effective probe placement, reduced time for TEE placement, and no reported adverse events.[1][4]

Therapeutic areas: PulmonologyNeurology
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

YKK Corp. of America (manufacturing partner for Evevo Manufacturing joint venture)

Beyond the preview

Go deeper on Visura Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Visura Technologies.

Explore the full profile